Modality
Fusion Protein
MOA
FcRni
Target
TROP-2
Pathway
Fibrosis
FL
Development Pipeline
Preclinical
~Mar 2019
→ ~Jun 2020
Phase 1
~Sep 2020
→ ~Dec 2021
Phase 2
Mar 2022
Phase 2Current
NCT06568751
1,342 pts·FL
2022-03→TBD·Not yet recruiting
1,342 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Trial Timeline
P2/3
Not yet…
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06568751 | Phase 2/3 | FL | Not yet recr... | 1342 | ORR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| NVS-4076 | Novartis | Preclinical | TROP-2 | |
| NVS-8902 | Novartis | Preclinical | TROP-2 | |
| ABB-2476 | AbbVie | Phase 1/2 | USP1 | |
| Zanumavacamten | GSK | Phase 2/3 | TROP-2 | |
| Suracagene | GSK | Phase 3 | PRMT5 | |
| REG-6699 | Regeneron | Phase 2/3 | TIM-3 | |
| ION-1378 | Ionis | NDA/BLA | TROP-2 | |
| Zanufutibatinib | Intra-Cellular | NDA/BLA | CD38 | |
| Nirafotisoran | Jazz Pharma | Phase 2/3 | TROP-2 | |
| ILM-4317 | Illumina | NDA/BLA | TROP-2 |